Evidence syntheses in the registry — page 4
140 documents of type evidence synthesis.
Documents
-
How is access to incretin-based obesity pharmacotherapy distributed, and what does the pattern of unregulated supply indicate about it?
Low05 Mar 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Larazotide acetate compared with the comparator used in its…
Moderate01 Mar 2025 -
Does treatment with a glucagon-like peptide-1 receptor agonist increase residual gastric content at the time of elective procedural sedation?
Low13 Feb 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Mazdutide maintained across the full duration of the contributing trials?
Moderate13 Feb 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Exenatide compared with its comparator?
High31 Jan 2025 -
What in-use period can be supported for a reconstituted research peptide solution?
Moderate23 Jan 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Maridebart cafraglutide compared…
Low21 Jan 2025 -
In the population defined for cognitive performance and neuroprotection, what is the incidence of adverse events leading to discontinuation with Semax compared with its…
Very low11 Jan 2025 -
In the population defined for cognitive performance and neuroprotection, what is the effect of Semax compared with the comparator used in its contributing trials on the…
Very low26 Dec 2024 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of CJC-1295 compared with the comparator used in…
Low12 Dec 2024 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the incidence of adverse events leading to discontinuation with…
Moderate08 Dec 2024 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
High27 Nov 2024 -
Synthesis: Maridebart cafraglutide in obesity and overweight in adults: effect on the anchor outcome
In the population defined for obesity and overweight in adults, what is the effect of Maridebart cafraglutide compared with the comparator used in its contributing…
Low13 Nov 2024 -
In the population defined for obesity and overweight in adults, is the effect of Orforglipron maintained across the full duration of the contributing trials?
Moderate09 Nov 2024 -
What is the effect of reconstitution practice on the dose actually delivered from a lyophilised research peptide?
Moderate05 Nov 2024 -
In the population defined for type 2 diabetes mellitus, what is the effect of Lixisenatide compared with the comparator used in its contributing trials on the anchor…
High01 Nov 2024 -
What is the relationship between the indications in which melanocortin receptor agonists have been evaluated and the uses under which they are supplied?
Low16 Oct 2024 -
In adults with heart failure with preserved ejection fraction and obesity, what is the effect of an incretin receptor agonist on symptoms and on heart-failure events?
Moderate11 Oct 2024 -
What can be concluded from a development programme that was discontinued, and how should the Institute record it?
Moderate09 Sep 2024 -
What is the evidence that glucagon-like peptide-1 receptor agonism increases the risk of medullary thyroid carcinoma in humans?
Low23 Aug 2024
page 4 of 4